Business
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Su
About this update from Scienture Holdings, Inc.
[{"type":"image","alt":"Scienture Holdings, Inc.","displaySize":"","headline":null,"caption":"Scienture Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/28b8170836e8ea967b4f044154f8d636"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/13RYlt0th1D5Rsmp1JUGQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/28b8170836e8ea967b4f044154f8d636","width":300,"height":51}},"lazy":false},{"type":"text","content":"TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension, while simultaneously announcing a temporary suspension of further ELOC draws for the next 30 trading days or until the company's stock reaches $10 per share, whichever occurs first.","length":700,"tagName":"p"},{"type":"text","content":"The strategic financial decision comes on the heels of today's announcement that the U.S. Food and Drug Administration (FDA) has approved Scienture's New Drug Application (NDA) for Arbli™, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market. The draw will provide immediate capital to support pre-launch activities for this novel antihypertensive medication.","length":399,"tagName":"p"},{"type":"text","content":""Following the momentous FDA approval of Arbli™ today, we have strategically accessed our Equity Line of Credit to ensure adequate capitalization for our commercial launch preparations," said Suren Ajjarapu, Chairman of the Board of Scienture Holdings, Inc. "Simultaneously, we believe it is in our shareholders' best interest to temporarily pause further draws from the ELOC as we navigate this exciting period in our company's growth trajectory."","length":476,"tagName":"p"},{"type":"text","content":"The company has committed to refraining from additional draws on the ELOC for either 30 t...